Home>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>Brevianamide F (Cyclo(L-Pro-L-Trp))

Brevianamide F (Cyclo(L-Pro-L-Trp)) (Synonyms: cyclo-(L-Trp-L-Pro), Cyclo-L-tryptophyl-L-proline)

Catalog No.GC30156

Brevianamide F (Cyclo(L-Pro-L-Trp)) (Cyclo(L-Pro-L-Trp)) is a mycotoxin isolated from Colletotrichum gloeosporioides, with antibacterial activity.

Products are for research use only. Not for human use. We do not sell to patients.

Brevianamide F (Cyclo(L-Pro-L-Trp)) Chemical Structure

Cas No.: 38136-70-8

Size Price Stock Qty
10mM (in 1mL DMSO)
$101.00
In stock
5mg
$92.00
In stock
10mg
$138.00
In stock
50mg
$414.00
In stock
100mg
$644.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Brevianamide F , also known as cyclo-(L-Trp-L-Pro), belongs to a class of naturally occurring 2,5-diketopiperazines.Brevianamide F possess interesting breast cancer resistance protein inhibitory activity.[1] brevianamide F once used as aromatic substrate. [2]

[1]. Wauters I et al. Beyond the Diketopiperazine Family with Alternatively Bridged Brevianamide F Analogues. J Org Chem, 2015 Aug 21, 80(16):8046-54. [2]. Yin S et al. Identification of a brevianamide F reverse prenyltransferase BrePT from Aspergillus versicolor with a broad substrate specificity towards tryptophan-containing cyclic dipeptides. Appl Microbiol Biotechnol, 2013 Feb, 97(4):1649-60.

Reviews

Review for Brevianamide F (Cyclo(L-Pro-L-Trp))

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Brevianamide F (Cyclo(L-Pro-L-Trp))

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.